Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment Charles River Laboratories International, Inc. (CRL) has announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to assess the abuse potential of new drugs. The agreement aims to enhance objective, standardized metrics for quantifying abuse potential in preclinical models, which may inform regulatory assessments of abuse potential under the Controlled Substances Act. The collaboration aims to improve public health safeguards and enhance efforts to protect patients and communities. Charles River has extensive expertise in assessing abuse potential, having conducted over 100 abuse potential studies and contributed to assessments of the abuse Potential of 15 FDA-approved products.
Publié : il y a 4 jours par Inc., Charles River Laboratories International dans Business Health Science
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitiv... [2995 symbols]
Les sujets: FDA
